Content about Specialty Pharmacy

September 16, 2010

An advisory committee of the Food and Drug Administration has given a thumbs-down to a...

SAN DIEGO An advisory committee of the Food and Drug Administration has given a thumbs-down to a drug for treating obesity.

 

Eisai and Arena Pharmaceuticals said Thursday that the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 9-5 to recommend against approval of the drug lorcaserin, saying clinical trial data did not adequately show that its benefits would outweigh its risks.

 

 

September 13, 2010

Biotech companies Seattle Genetics and Genmab will collaborate to develop antibody treatments for cancer, the...

BOTHELL, Wash. Biotech companies Seattle Genetics and Genmab will collaborate to develop antibody treatments for cancer, the two companies announced Tuesday.

 

Seattle Genetics, based in the Seattle suburb of Bothell, Wash., and Denmark-based Genmab will develop the treatments using Seattle Genetics’ antibody-drug conjugate technology. Seattle Genetics received an undisclosed upfront payment and will have the right to exercise a co-development option for any products at the end of early-stage clinical development.

 

 

September 12, 2010

The Food and Drug Administration has accepted a regulatory approval application for a flu vaccine...

SWIFTWATER, Pa. The Food and Drug Administration has accepted a regulatory approval application for a flu vaccine administered in the skin.

 

Sanofi Pasteur, the vaccines arm of French drug maker Sanofi-Aventis, announced Monday that the FDA had accepted its application for Fluzone Intradermal (influenza virus vaccine). The company expects the FDA to take action on the vaccine in the first half of next year.

 

 

September 12, 2010

The Food and Drug Administration did not completely withdraw from the market a drug used...

PHILADELPHIA The Food and Drug Administration did not completely withdraw from the market a drug used to treat a dangerous low blood pressure condition, but merely proposed to do so as a “step in the regulatory process,” according to a document posted on the agency’s website Monday.

The agency said its proposal last month to withdraw approval for Shire’s drug ProAmatine (midodrine) did not represent the actual withdrawal of the drug from the market, while calling for more data on the drug to verify its clinical benefit.

 

September 12, 2010

An investigational treatment for HIV by Gilead Sciences that combines four drugs in one tablet...

FOSTER CITY, Calif. An investigational treatment for HIV by Gilead Sciences that combines four drugs in one tablet works as well as a drug already on the market, Gilead said Monday.

 

September 9, 2010

Close to 400 drugs and vaccines are in development for fighting infectious diseases, according to...

BOSTON Close to 400 drugs and vaccines are in development for fighting infectious diseases, according to one of the pharmaceutical industry’s largest lobbying groups.

 

The Pharmaceutical Research and Manufacturers of America announced Friday that drug makers have 395 new medicines and vaccines in clinical development or under review by the Food and Drug Administration. These include five vaccines and six drugs for malaria, as well as agents for infections like cholera, methicillin-resistant Staphylococcus aureus and the Ebola virus.

 

September 9, 2010

Diplomat Specialty Pharmacy isn’t the only one to earn a spot on Inc. magazine’s list...

September 8, 2010

Inc. magazine has ranked Diplomat Specialty Pharmacy as one of the fastest-growing private companies in...

September 8, 2010

NEW YORK British drug maker GlaxoSmithKline and biotech company Genmab have started a late-stage trial...

NEW YORK British drug maker GlaxoSmithKline and biotech company Genmab have started a late-stage trial of a biotech drug for treating cancer, the two companies said.

 

September 8, 2010

British drug maker Shire is working with Cambridge, Mass.-based Acceleron Pharma to develop treatments for...

CAMBRIDGE, Mass. British drug maker Shire is working with Cambridge, Mass.-based Acceleron Pharma to develop treatments for serious muscular disorders, Shire said Thursday.

 

The drug maker announced that the two companies would investigate ACE-031, a drug in mid-stage clinical trials as a treatment for Duchenne muscular dystrophy, a rare and fatal muscle disorder with no current treatment. The drug belongs to a class known as activin receptor type IIB, or ActRIIB molecules.

 

 

September 6, 2010

Biotech drugs for treating Alzheimer’s disease will more than triple the size of the market...

September 2, 2010

Pfizer is pulling out of a development deal for a potential brain cancer drug, saying...

NEEDHAM, Mass. Pfizer is pulling out of a development deal for a potential brain cancer drug, saying it is not a strategic priority, according to the drug's developer Celldex Therapeutics.

Celldex said it will regain full worldwide rights to develop and sell rindopepimut from Pfizer. The drug candidate also is called CDX-110. In May, the company reported positive results form a midstage study on the drug.

 

Celldex will regain rights to the drug candidate on Nov. 1.

 

August 31, 2010

A specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes...

August 31, 2010

The Food and Drug Administration has granted priority review for a diabetic macular edema treatment....

ATLANTA The Food and Drug Administration has granted priority review for a diabetic macular edema treatment.

August 31, 2010

Pfizer announced Wednesday that it will acquire a privately held drug discovery and clinical development...

August 30, 2010

The U.S. drug market will present opportunities as well as uncertainties over the next decade,...

SAN DIEGO The U.S. drug market will present opportunities as well as uncertainties over the next decade, according to remarks made by IMS Health VP industry relations Doug Long at the National Association of Chain Drug Stores’ 2010 Pharmacy and Technology Conference held here on Monday.

 

August 29, 2010

BioMarin Pharmaceutical on Monday announced its investigational treatment for a lysosomal storage disorder has received...

August 29, 2010

Meda on Monday announced an agreement to acquire the specialty pharmaceutical company Alaven in a...

STOCKHOLM Meda on Monday announced an agreement to acquire the specialty pharmaceutical company Alaven in a move that will “significantly enhance Meda’s marketing capabilities in the United States and expand the therapeutic focus to include both gastroenterology and women’s health — areas that Meda already operates in outside of the United States,” the company stated.

 

Meda also identified Alaven’s over-the-counter platform, which accounts for approximately 25% of Alaven’s sales, as an attractive element to the deal.

August 29, 2010

The Apothecary Shops, a Phoenix-based chain of specialty pharmacies with 16 locations in six states,...

PHOENIX The Apothecary Shops, a Phoenix-based chain of specialty pharmacies with 16 locations in six states, has acquired the Greater Sacramento Specialty Pharmacy.

GSP, which provides services to patients and practitioners in California, Oregon, Nevada, Washington, Idaho and Montana, will be a wholly owned subsidiary of The Apothecary Shops and will continue operating under the Greater Sacramento Specialty Pharmacy name. The acquisition of GSP bolsters the oncology specialty business for The Apothecary Shops. Financial terms of the deal were not disclosed.

August 25, 2010

The Department of Health and Human Services on Wednesday expanded Medicare coverage of evidence-based tobacco-cessation...

WASHINGTON The Department of Health and Human Services on Wednesday expanded Medicare coverage of evidence-based tobacco-cessation counseling, removing a barrier to treatment for all tobacco users covered by Medicare, the Centers for Medicare and Medicaid Services announced.

 

August 23, 2010

Swiss drug maker Roche will acquire a U.S. diagnostics company that develops technology used to...

BASEL, Switzerland Swiss drug maker Roche will acquire a U.S. diagnostics company that develops technology used to create images of patients’ tissue samples.

Roche announced that it would acquire all of Sunnyvale, Calif.-based BioImagene for $100 million. BioImagene works in the field of digital pathology, a technology that allows the capturing, management and analysis of images of patients’ tissue samples, creating high-resolution images from glass microscope slides.

August 19, 2010

Sales at Assured Pharmacy rose 1.4% in July over the month before, the specialty pharmacy...

August 19, 2010

BioMarin Pharmaceutical has acquired privately owned biotechnology company ZyStor Therapeutics for $22 million, BioMarin said....

August 19, 2010

An anti-inflammatory drug approved 60 years ago may help fight against a fungal infection of...

August 17, 2010

The Food and Drug Administration has agreed to expedite review of an investigational treatment for...